3 days Ago By ABMN Staff
Ventum Cap Mkts upgraded shares of Sernova ( TSE:SVA – Free Report ) to a strong-buy rating in a research report released on Thursday morning, Zacks.com reports. Several other equities research analysts have also weighed in on the company.
Leede Financial decreased their price objective on Sernova from C$3.00 to C$1.50 and set a speculative buy rating for the company in a report on Friday.
Ventum Financial reduced their target price on shares of Sernova from C$3.00 to C$2.50 and set a buy rating for the company in a report on Friday.
Read Our Latest Report on SVA Sernova Stock Performance Sernova ( TSE:SVA – Get Free Report ) last announced its earnings results on Friday, June 14th. The company reported C($0.03) earnings per share for the quarter, meeting the consensus estimate of C($0.
03). Equities analysts predict that Sernova will post -0.08 EPS for the current year.
Insider Activity at Sernova In other news, Director Steven Sangha sold 930,000 shares of the stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of C$0.24, for a total transaction of C$223,200.
00. Insiders have purchased a total of 359,600 shares of company stock valued at $92,771 in the last 90 days. 12.
98% of the stock is owned by corporate insiders. About Sernova ( Get Free Report ) Sernova Corp. operates as a clinical-stage regenerative medicine therapeutics company in Canada.
The company focuses on the development and commercialization of regenerative medicine therapeutics, including its proprietary Cell Pouch and associated technologies consisting of therapeutic cells and local cellular immune protection. Featured Articles Receive News & Ratings for Sernova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sernova and related companies with MarketBeat.com's FREE daily email newsletter .
.
